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Objective: We evaluated the long-term prognosis of stents placed on an 
emergency basis in the trachea and its bifurcation for malignant stenosis. 
Methods: We retrospectively analyzed all bronchologic treatments of obstruct- 
ing airway lesions from January 1993 to December 1995. Results: We report on 
10 patients with severe malignant "mixed-type" obstruction of the proximal 
trachea or distal trachea plus both main-stem bronchi. They had far-advanced 
inoperable tumor (esophageal cancer: n = 4; lung cancer: n = 3; recurrent 
laryngeal, uvula, and thyroid cancer: n = 1 each). Emergency treatment 
consisted of a dilating bougie maneuver followed by the insertion of a large 
one-way (n = 4) or Y-shaped silicone prosthesis (n = 6). After the intervention, 
there was a long-lasting clinical improvement. Median survival from stent 
insertion was 8 months for all patients irrespective of tumor type; it was 5 
months for patients with lung carcinoma and 8 months for those with 
esophageal cancer. The results are in accordance with other studies using 
different herapeutic modalities. Stent exchange was necessary in five patients. 
Main reasons were continuing tumor growth beyond the proximal and distal 
boundaries and recurrent productive bronchial infection. Patients died of 
pneumonia (n = 4), pulmonary lymphatic spread (n = 1), cardiac failure (n = 
2), and fatal hemorrhage (n = 1). As of December 1995, three patients were 
still alive 2, 5, and 8 months after implantation. Conclusions: As evidenced by 
clinical efficiency and length of palliation, endoscopic placement of silicone- 
based one-way and bifurcational prostheses in far-advanced tumor of the 
central airways is technically feasible and ethically justifiable. (J Tborac 
Cardiovasc Surg 1996;112:859-66) 
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U ntil recently, obstructive lesions of the central airways caused by extrinsic tumor growth neces- 
sitated open surgical procedures to restore the 
lumen. A tracheostomy was the therapy of choice 
whenever the subglottic area was involved. How- 
ever, processes located both in the distal trachea 
and in the bifurcation were extremely difficult to 
address: Mechanical debulking of the infiltrated 
mucosa was short-lived. Extrinsic compression, on 
the other hand, precluded endoscopic resection. 
With the advent of cylindrical and bifurcated 
silicone prostheses, longstanding patency can be 
achieved by means of bronchoscopic techniques 
alone. These new devices may provide valuable 
palliation for patients with inoperable malignant 
disease of the central airways. 
Patients and methods 
In a retrospective analysis of bronchoscopie nterven- 
tions from January 1993 to December 1995, only patients 
with malignant obstruction of the trachea or tracheobron- 
chial bifurcation, or both, were considered. They were 
selected from 53 patients who had endoscopic treatment 
of malignant obstructing airway lesions during that period. 
As we focused on the "natural history" of stents in the 
upper airways, we excluded patients who underwent air- 
way recanalization without insertion of stents or with 
stents placed at more distal sites. In addition, we excluded 
those who needed only transient support by a prosthesis to 
bridge the delay until decompression was achieved by 
other well-established techniques. 
When the patients arrived at the bronchology unit, 
14.6 + 19 months (mean + standard eviation; median 8 
months; range 0 to 60 months) had passed since the initial 
diagnostic workup (Table I). As first-line therapy three 
patients had undergone surgical resection with intention 
for cure. Seven patients had been pretreated with stan- 
dard radiotherapy orchemotherapy, or both. The present- 
ing sign was respiratory distress. Complaints of gradually 
worsening stridor over the previous weeks or months had 
been attributed to symptoms of acute upper airway infec- 
tion. 
Bronchoscopic examination revealed local tumor inva- 
sion along with considerable stenosis of the trachea lone 
(n = 4) or of both the trachea nd carina involving the 
ostium of the main-stem bronchi (n = 6). In every single 
case the obstructive l sion was of the mixed type, that is, 
composed of extrinsic ompression and mucosal infiltra- 
tion and congestion. 
Biopsy sampling yielded esophageal cancer in four 
patients, small-cell and non-small-cell bronchogenic car- 
cinoma in three, thyroid carcinoma nd uvula carcinoma 
in one patient each, and recurrent laryngeal carcinoma in 
one patient who had a tracheostomy after complete 
laryngectomy. All tumors were inoperable at presentation. 
Short-term management. The patients needed urgent 
dilation and stenting of the central airways to avoid 
imminent asphyxia. 
With the patient under general anesthesia orolaryngeal 
intubation was performed with an operating laryngoscope 
attached to a chest support (Karl Storz, Tuttlingen, Ger- 
many). The tip of the laryngoscope had an internal 
diameter of 20 mm. It was positioned to expose the entire 
circumference of the vocal cords. Ventilation was sus- 
tained by a low-frequency oxygen jet through a nozzle 
fixed to the proximal orifice of the instrument. The 
laryngoscope thus served as an access for manipulations 
necessary within the trachea. At the same time, it allowed 
continuous administration of oxygen. 
Emergency treatment consisted of a bougie maneuver 
in which a series of rigid bronchoscopes of increasing 
diameters were used. In all patients, placement of the 
appropriate stents (Fig. 1) was facilitated by use of the end 
of the bronchoscope to peel off the congested mucosa. For 
the insertion of the cylindrical Dumon stents (n = 4; 16 
mm outer diameter; Dumon Stent Endoxane, distributed 
by Bess Medizintechnik GmbH, Berlin, Germany), 1 a 
metal or plastic tube was used with a pusher inside. After 
the stent was folded into the tip of the tube, the applicator 
was introduced into the trachea nd passed just beyond 
the previously dilated stenosis. Then the tube was drawn 
back over the pusher so that the stent was released into 
the obstructed segment (Fig. 2, A). Whenever subsequent 
fiberoptic bronchoscopic examination i dicated the need 
to move the prosthesis, it was moved into the correct 
location with the help of a rigid forceps. 
Atraumatic placement of a bifurcated Dynamic stent 
(n = 6; 13 or 15 mm outer diameter at the distal tracheal 
portion; Dynamic Stent, produced by Willy Rfisch AG, 
Kernen, Germany) 2 necessitated that its divergent main- 
stem limbs be held together from the inside by the 
branches of a foreign body forceps. Passage through the 
vocal cords was eased by turning the stent on its long axis 
so that the two limbs were in line with the glottis. The 
prosthesis could then be advanced without difficulty. Once 
within the trachea, the stent was turned back to its normal 
position and was pushed further down to be firmly an- 
chored on the carina. Usually, the limbs readily entered 
their respective main-stem bronchi themselves (Fig. 2, B). 
In case of kinking or infolding, a flexible bronchoscope 
inserted into the limbs helped to deploy them and served 
as a "guidewire." 
Results 
Preimplantation versus postimplantation lung 
function values were available for comparison in five 
patients (Table II). Before intervention, peak expi- 
ratory flow and forced expiratory volume in 1 second 
(FEV1) were clearly reduced and body plethysmo- 
graphic airway resistance, which showed a typical 
S-shaped flow-pressure loop, was elevated. 3 Vital 
capacity was in the low normal range. Stent place- 
ment resulted in a median increase of peak expira- 
tory flow and FEV1 by 92% and 54%, respectively, 
airway resistance fell by a median of 48% from the 
preimplantation value, and vital capacity remained 
essentially unchanged. 
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Table I. Patient characteristics 
Follow-up (too); ID to 
Patient Tumor site, growth characteristics, BU*" BU to death or 
(sex, age) Diagnosis and management N L and complications 12/957 
1 (F, 51) Esophageal Ca, T4 N1 M1 (pul). After radio- 1 + Subtotal proximal tracheal steno- 5 mo;* 2 mo.t Died of 
therapy; mechanical dilation, Dumon (16), sis due to extrinsic ompression resp. failure, Ca 
RT and mucosal congestion, lymphangitic. 
Esophageal Ca, T4 N1 M0; mechanical dila- Subglottic tracheal obstruction 1 mo*; 12 mo.~ Tu- 
tion, Dumon (16), RT, chemotherapy due to extrinsic ompression mor progression 
and mucosaI infiltration. Later Died of pneumonia. 
subglottic fistula. 
Subglottic tracheal stenosis due to 
extrinsic ompression and infil- 
tration. 
Mid-to-lower tracheal compres- 
sion and infiltration, esophageal 
infiltration, middle lobe bron- 
chial obstruction. Tracheoesoph 
fistula subsequent to chemo- 
therapy. 
Distal one third of trachea, bifur- 
cation; wall destruction, intralu- 
minal growth, carinal compres- 
sion. 
Distal trachea, bifurcation, RMB/ 
LMB swollen and distorted by 
infiltrating tumor. 
2 (M, 58) 1 + 
3 (M, 66) Esophageal Ca, T4 N1 M0; RT; mechanical 1 NA 
dilation, Dumon (16) 
4 (F, 69) SCLC, T4 N3 M0, extensive disease; mechan- 1 + 
ical dilation, Dumon (16), chemotherapy 
5 (F, 58) Tracheal recurrence of papillar thyroid Ca. 3 NA 
After total thyroidectomy and radiother- 
apy; laser resection, mechanical dilation, 
Dynamic stent (15) 
6 (M, 66) Tracheal and carinal recurrence of uvula Ca. 2 NA 
After resection and radiotherapy; laser re- 
section, mechanical dilation, brachytherapy, 
Dynamic stent (13) 
7 (M, 62) NSCLC, T4 N3 M0. Local recurrence after 4 + 
combined radio/chemotherapy, mechanical 
dilation, Dynamic stent (15) + Dumon 
(13), brachytherapy 
8 (M, 61) 
9 (M, 45) 
10 (M, 53) 
NSCLC, T4 N3 M1 (hep); superior vena cava 1 NA 
syndrome. First presentation; mechanical 
dilation, Dynamic stent (13), RT 
Esoph. Ca, T4 N2 M1 (cer, oss). Esoph. tub- 5 + 
ing, chemotherapy, RT, mechanical dila- 
tion, recanalization, Dynamic stent (15), 
Dumon (13), brachytherapy and Dumon 
(16) 
Tracheal recurrence of pharynx Ca. After 2 NA 
resection and radiotherapy; T3 N2 M0; 
Dynamic stent (13) 
Distal trachea, bifurcation, RMB/ 
LMB infiltrated; Proteus vul- 
garis. 
Distal trachea, bifurcation, RMB/ 
LMB infiltrated. 
Tumor infiltrating distal trachea 
and LMB, fistula, tumor infil- 
tration of RMB and LMB; 
Pseudomonas aeT~lginosa. 
Tumor compression of whole tra- 
chea distal to tracheostomy; 
Staphylococcus aureus. 
4 mo*; 8 mo.-~ Died of 
cardiac failure and 
pneumonia. 
0 mo*; >2 mo.t 
33 mo*; 12 mo.f Stent 
exchange due to 
kinking. Died of 
cardiac failure. 
60 too*; 8 rno.t Stent 
exchange due to 
tumor overgrowth. 
Died of recurrent 
pneumonia. 
17 mo*; 8 mo.~ Stent 
exchanges due to 
dislodgment and 
restenosis by tumor 
overgrowth. Died of 
fatal hemorrhage. 
0 too*; >5 mo.t Clini- 
cal improvement. 
11 too*; >8 mo.t 
Stent placement at 
restenosis and tu- 
mor overgrowth. 
15 mo*; 3 mo.f Stent 
exchange due to 
multiresistant Staph. 
Died of pneumonia 
Ca, Carcinoma; RT, radiotherapy, SCLC, small-cell ung carcinoma; NSCLC, non-small-cell lung carcinoma; pul, pulmonary metastases; hep, hepatic 
metastases; cer, cerebral metastases; o s, osseous metastases; N, number of stents implanted consecutively or simultaneously; L, lung function before and after 
implantation; +,available; NA, not available; RMB/LMB, right/left main-stem bronchus; ID, time of initial diagnosis; BU, first appearance in bronchology unit; 
13, 15, 16, outer diameter in millimeters (only most recent stents are given). Data as of December 31, 1995. 
After a successful primary endoscopic treatment, 
five of 10 patients needed replacement of stents, 
such that a total of 21 devices were implanted 
consecutively or simultaneously (Table III). The 
first exchange was 3.8 + 1.8 months (mean + 
standard eviation) from the initial bronchoscopic 
treatment (n = 5), the second occurred 2.0 _+ 0.9 
months later (n = 3), and one patient had a third 
exchange after another 2.5 months. The need for 
restenting seemed to depend on the presence or 
absence of subsequent radiotherapy and chemother- 
apy (see Table I). In case these options had already 
been exhausted before the first stent placement and 
continuing tumor growth beyond the boundaries of 
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Fig. 1. The two types of silicone stents described in the 
current study. Top, A full-length Dynamic bifurcated 
prosthesis. Both the tracheal portion (horseshoe stainless 
steel inlays) and either main stem limb can be shortened 
to the appropriate length. Bottom, A Dumon radiopaque 
tracheal prosthesis. 
the prosthesis led to restenosis, the lesions were 
then bridged by longer and more appropriate de- 
vices. Because in two patients the limbs of a Dy- 
namic stent could not be introduced through a 
complex conical stenosis of the main-stem bronchi, 
these obstructions were bridged by short Dumon 
tubes before the remainder of the bifurcational 
narrowing was stented with a Dynamic prosthesis. 
Thus two serial stents were necessary (Fig. 3). A 
course of brachytherapy was added to improve 
sustained airway patency at the distal edges. 
A further important reason for stent exchange 
was recurrent bronchial infection (n = 3). The 
patients complained of purulent secretions and bad 
breath. One of them had a tracheostomy after a 
laryngectomy. Bacterial bronchitis developed as a 
result of multiresistant Staphylococcus aureus organ- 
isms colonizing on the silicone material. Lavage in 
two more patients yielded Proteus mirabiIis and 
Pseudomonas aeruginosa bacteria on several occa- 
sions. From the explanted stent material, Candida 
albicans, Staphylococcus aureus, and Proteus mirabi- 
lis could be cultured. Despite effective antibiotic 
therapy, the infection recurred after short disease- 
free intervals. 
In one patient a tracheoesophageal fistula devel- 
oped underneath t e stent after completion of the 
first chemotherapy course directed against extrinsic 
invading small-cell ung carcinoma. The stent re- 
mained in place and the fistula was sealed with an 
additional esophageal prosthesis. Significant reste- 
nosis from mucus impaction or granulation tissue 
was not encountered. Nonproductive cough caused 
by foreign body irritation was rare. 
As of December 31, 1995, all patients had sur- 
vived for a mean of 6.8 + 3.7 months (median 8 
months) after their first arrival in the bronchology 
unit. The replacement group had an entire fol- 
low-up of 7.8 _+ 3.2 months, whereas the remain- 
ing five patients with one stent only survived for 
5.8 -+ 4.3 months. The difference was not signifi- 
cant. 
No deaths occurred within 30 days of interven- 
tion. Causes of death were cardiac (n = 2) and 
respiratory failure (n = 5); the latter was due to 
carcinomatous lymphangitis and pneumonia. One 
patient died of acute hemorrhage during stent re- 
placement. The fatal event occurred uring endo- 
scopic manipulation of a tumor-infiltrated bronchial 
wall adjacent to the pulmonary artery. 
Three patients were still alive at the time of this 
writing 2, 5, and 8 months after implantation. 
Discussion 
Among the different echniques to restore pa- 
tency in malignant obstructive l sions of the upper 
airways, stents are the mainstay. They establish 
immediate luminal patency and thus have a signifi- 
cant role in respiratory emergencies. Furthermore, 
they are thought to prevent long-term restenosis. In
our opinion, therefore, placement of expandable 
metallic prostheses 4 is obsolete, because they allow 
continuous tumor growth through the wires of the 
stent and secondary obstruction within. 
The decision to introduce a tracheobronchial 
stent depends on (1) the type of growth of the 
malignant process, (2) the site of the stenosis, and 
(3) the severity of dyspnea, generally reflecting the 
amount of reduced luminal diameter. 
High-grade xtrinsic ompression of the trachea 
or carina by mediastinal malignant tissue with or 
rarely without additional wall infiltration requires 
prompt prosthetic placement. The same applies to 
tumor-induced tracheomalacia because the wall is 
liable to collapse with every expired breath. Under 
these circumstances, no other therapy but stent 
repair provides immediate relief and permanent 
airway patency, if chemotherapy and radiotherapy 
options have been exhausted during previous trials. 
Both slight to moderate stenosis of the central 
airways and any variant of malignant obstruction at 
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Fig. 2. Drawing of stenting techniques. A, Dumon stent implantation via operating laryngoscope. Top, 
Applicator pushed beyond tracheal stenosis. Inset and bottom, Stent release by drawing the tube against he 
pusher. For details see text. B, Dynamic stent placement via operating laryngoscope. Top, Stent inserted 
with a rigid foreign body forceps whose branches put the divergent limbs together (bottom right). Bottom 
left, Stent anchored on the carina with the limbs in place. For details ee text. 
Table II. Lung function results before and after emergency stenting in five patients 
Patient PEF Raw FEVe VC 
1 
Before 0.56 (8.5%) 1.56 (519%) 0.72 (26%) 2.48 (75%) 
After 4.05 (+623%) 0.81 (-48%) 2.52 (+250%) 2.63 (+6%) 
Before 4.30 (49%) 0.47 (160%) 2.69 (75%) 5.07 (108%) 
After 6.37 (+48%) 0.15 (-68%) 4.00 (+48%) 4.99 (-1.6%) 
Before 1.28 (25%) 1.35 (449%) 0.96 (60%) 2.09 (102%) 
After 2.99 (+ 133%) 0.34 (-75%) 1.48 (+54%) 2.04 (-2.4%) 
Before 2.33 (30%)* 0.56 (187%) 1.48 (50%) 2.88 (74%) 
After 4.48 (+92%)t 0.40 (-29%) 2.12 (+43%) 3.15 (+9%) 
Before 4.58 (48%) 0.42 (141%) 2.56 (61%) 4.15 (76%) 
After 6.03 (+31%) 0.31 (-26%) 4.00 (+56%) 5.32 (+28%) 
Median* 30 187 60 76 
Delta mediant +92 -48 +54 +6 
PEF, Peak expiratory flow (L/sec); Rag,, body plethysmographic airway resistance (kPa × sec/L); FEV1, forced expiratmy volume in 1 second (L); VC, vital 
capacity (L). 
*Percent predicted normal. 
tPercent deviation from preimplantation value (=100%). 
more distal sites can await gradual reopening 
achieved by chemotherapy, external-beam radio- 
therapy, or bronchoscope-guided brachytherapy. In 
addition, mere intraluminal tumor growth does not 
necessitate stents in any location. Tumor debulking 
with a rigid forceps or coring with a rigid broncho- 
scope 5 will suffice as a first-line measure. Some 
authors prefer laser resection, 6' 7 the use of a dia- 
thermy loop, 8 or electrocautery 9 to remove neoplas- 
tic tissue of this type. 
In our series, after the intervention all patients 
had dramatic linical improvement, best reflected by 
the relative change of peak expiratory flow. Peak 
expiratory flow is the most sensitive parameter for 
upper airway disease in model experiments. 3 Me- 
dian survival was 8 months from the time of stent 
placement irrespective of histologic tumor type. 
Therefore long-standing local tumor control can be 
obtained with the help of stents in malignant lesions 
of the upper airways. However, a clear-cut survival 
8 6 4 Wassermann et aL 
The Journal of Thoracic and 
Cardiovascular Surgery 
October 1996 
Table III. Reasons for stent exchange 
Insufficient closure of fistula 1 
Tracheal kinking 1 
Stent dislodgment 1 
Tumor overgrowth at proximal or distal ends 5 
Growth and adherence of (multiresistant) bacteria 3 
benefit does not seem to be derived from placement 
of a permanent prosthesis alone. All patients had 
had additional treatments with radiotherapy or che- 
motherapy, orboth, before or after stenting. Median 
overall survival (i.e., from initial diagnosis to death) 
for those who had esophageal cancer (n = 4) was 
12.5 months. This survival time is not different from 
that in a recently published study of radiotherapy 
and chemotherapy of inoperable sophageal can- 
cer. 1° Median survival was 12.5 months for the 
combination protocol and 8.9 months for radiother- 
apy only. In contrast to our patients, a great majority 
of the study participants were recruited at earlier 
(i.e., T2) tumor stages. Moreover, a survival analysis 
of the subgroup of patients who had complicating 
metastatic obstruction of the upper airways is miss- 
ing. 
Patients with lung cancer (n = 3) survived a 
median of 5 months from the time of stent place- 
ment. This survival time compares favorably with 
other recently published data on brachytherapy 
(median survival 4.5 months) 11 and endobronchial 
laser resection (median survival 6 months) 6 of far- 
advanced inoperable obstructive bronchogenic car- 
cinomas. Again, patients with tumor involvement of
the trachea, who made up only 10% and 25% of the 
respective total study populations, were not consid- 
ered as subgroups of their own. A most recent 
article on permanent racheobronchial silicone 
stents (Dumon) inserted for palliation of obstruct- 
ing cancer of various histologic types 12 found me- 
dian survivals of 6 and 4 months for the stage IIIB 
lung cancer groups with or without additional radio- 
therapy. The difference between these two samples 
was not significant. Although only 43% of tumors 
involved the trachea, the survival results agree with 
our findings. The issue of location and survival is still 
unresolved. However, one could speculate that tu- 
mor growth involving the trachea or carina is asso- 
ciated with less serious complications and longer 
survival than more distally located airway lesions, 
once satisfactory patency can be obtained. Malig- 
nant stenosis of main-stem, intermediate, or lobar 
bronchi may produce lung compromise such as 
Fig. 3. Chest x-ray film of patient 9 with three serial 
tracheobronchial stents (Dumon 16 m, Dynamic 15 mm, 
Dumon 13 mm). An esophageal tube had been inserted 
before. 
atelectasis, econdary pneumonia, nd abscess for- 
mation before patients are referred to the bron- 
chologist. Recanalization will then often be unre- 
warding. Interestingly enough, for our experience, 
patients with stents inserted into these distal sites 
had a 30-day mortality of about 25% (unpublished 
data), as compared with no early deaths in those 
undergoing stent placement in the obstructed upper 
airways. 
Bacterial adherence to intravascular o intracavi- 
tary plastic devices uch as catheters, biliary stents, 
and drainage tubes poses a major problem because 
it occasionally causes infections and septic compli- 
cations.13, 14The chemical composition of the mate- 
rial may determine the amount of adherence: Poly- 
urethane pieces coated with synthetic hydrophilic 
monomers eem less likely to attract and deposit 
bacteria than are uncoated tubes made of polyeth- 
ylene or silicone rubber. 13-15 It is also conceivable 
that the number of colonizing strains per surface 
area should increase as indwelling time increases. In 
addition, we postulate that both silicone biodeterio- 
ration 16 and limited clearance of secretions from 
within the tubes may contribute to the high affinity of 
microbes to the foreign material. In our patients either 
cultures of bacteria and yeasts from the explanted 
stents or recurrent bronchitis with the same gram- 
negative strain argue strongly in favor of adherence to
and colonization on plastic. Fatal pneumonias in some 
patients may thus have been induced. Even in the 
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absence of overt pneumonia, however, relapsing puru- 
lent sputum production i deed is a serious ide effect 
of stents that necessitates removal. Because of the 
focus on acute effects of airway stents, this issue is 
clearly underreported in the current literature. I7 In 
any case, this complication should stimulate research 
into less adherent or more bactericidal materials des- 
ignated for long-term use. 
Minor stent-related complications like kinking, 
dislodgment, and even dried secretions are forsee- 
able and can be handled with ease. 17 However, like 
Bolliger and coworkers, 12 we were concerned about 
one case of acute fatal hemorrhage occurring during 
stent extraction. After the end of the study period 
we saw another similar case. The underlying cause 
was presumably not stent-related, although pres- 
sure-induced necrosis of the bronchial wall and 
neighboring vascular structures cannot be entirely 
precluded. It is rather suggested that previous 
brachytherapy at this particular site may have con- 
tributed significantly to the fatal event. The preva- 
lence of spontaneous late massive hemoptysis in 
patients undergoing endobronchial brachytherapy 
ranges from 20% to 50%. 11 The reason is thought to 
be radiation-induced tumor necrosis involving the 
large pulmonary vessels in proximity to a friable 
main-stem bronchus. 18 In our patient, endobron- 
chial irradiation had been instituted because of 
recurrent malignant stenosis at the very distal edge 
of the right limb of a Dynamic stent. Information 
regarding changes in stent material (flexibility, brit- 
tleness) caused by brachytherapy are sparse. But the 
issue is rather speculative, because at a usual after- 
loading course, with the radiation source inside the 
stent, the interior surface will receive a total amount 
of four times 15 to 30 Gy, which is but a small 
fraction of the 5 to 10 kGy that the material is 
exposed to during the production process (Rfisch, 
personal communication, March 1996). On the 
other hand, because of the distancing effect of the 
prosthesis tself, the tissue underneath e stent will 
absorb less energy than the adjacent stent-free bron- 
chial segment. Thus, in combination with brachy- 
therapy, it is not stents that make the bronchial wall 
more vulnerable, it is brachytherapy alone. How- 
ever, a single delicate touch on the damaged bron- 
chus during stent exchange sufficed to precipitate 
rupture and fatal hemorrhage. Therefore manipu- 
lating stents within a region of previous brachyther- 
apy is strongly discouraged. 
In conclusion, Dumon and Dynamic silicone 
stents are most valuable tools to promptly restore 
sustained patency in tumor-obstructed upper air- 
ways. The effect on survival equals that of other 
antineoplastic modalities in patients in whom the 
trachea or bifurcation is not involved in the malig- 
nant process. Quite a few stents were exchanged 
every 2 to 4 months from the preceding treatment. 
The main reasons for replacement were tumor 
overgrowth and purulent bronchitis. 
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